Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Antineoplastic Agents

All Drugs and Chemicals

Sorafenib

Brivanib 800 mg, QD

Brivanib 400 mg, BID

This is a Phase 2, Open-label, Randomized, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Brivanib in Patients with Previously Treated Advanced Hepatocellular Carcinoma.

A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

A Multicenter, Randomized, Open-label, Phase II Clinical Study to Evaluate the Efficacy and Safety of Brivanib Alaninate (ZL-2301) Combined With Best Supportive Care (BSC) and Pharmacokinetic Profiles of Brivanib Alaninate in Patients With Advanced Hepatocellular Carcinoma (HCC) Failed or Intolerant of Standard Systemic Chemotherapy and/or Sorafenib

Defined as the percentage of patients with complete response, partial response, or stable disease at 12 weeks from randomization by RECIST v1.1.

Defined as the time from random assignment to radiologic disease progression.

Defined as the percentage of patients with complete response, partial response, or stable disease at 24 weeks from randomization by RECIST v1.1.

Defined as the time from random assignment until the date of disease progression or death as a result of any cause.

Defined as the proportion of randomized patients with CR or PR as the optimal response in each treatment group assessed by use of RECIST 1.1 criteria

Refers to the duration from randomization to death from any cause

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC	NCT03516071	Hepatocellular ...	Brivanib 800 mg... Brivanib 400 mg...	18 Years - 75 Years	Zai Lab (Hong Kong), Ltd.
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC	NCT03516071	Hepatocellular ...	Brivanib 800 mg... Brivanib 400 mg...	18 Years - 75 Years	Zai Lab (Hong Kong), Ltd.

Spots Global Cancer Trial Database for brivanib 400 mg, bid